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Acute graft-versus-host disease (GvHD) is a major
cause of mortality in allogeneic bone marrow
transplantation (BMT), for which administration of
FoxP3+ regulatory T (Treg) cells has been proposed
as a therapy. However, the phenotypic stability of
Treg cells is controversial, and STAT3-dependent
cytokines can inhibit FoxP3 expression. We as-
sessed whether the elimination of STAT3 in T cells
could limit the severity of GvHD. We found STAT3
limited FoxP3+ Treg cell numbers following alloge-
neic BMT by two pathways: instability of natural
Treg (nTreg) cells and inhibition of induced Treg
(iTreg) cell polarization from naive CD4+ T cells.
Deletion of STAT3 within only the nTreg cell popu-
lation was not sufficient to protect against lethal
GvHD. In contrast, transfer of STAT3-deficient naive
CD4+ T cells increased FoxP3+ Treg cells post-BMT
and prevented lethality, suggesting that the conse-
quence of STAT3 signaling may be greater for iTreg
rather than nTreg cells during GvHD.
INTRODUCTION
Allogeneic bone marrow transplantation (BMT) can be a life-
saving therapy for treatment of relapsed acute leukemia and
lymphoma, as well as inherited disorders of the bone marrow
(BM) and immune system (Atkinson, 1992). However, its
efficacy is limited by the morbidity and mortality associated
with graft-versus-host disease (GvHD). Acute GvHD is associ-
ated with activation of donor T cells and their secretion of
proinflammatory cytokines, resulting in inflammation in the
gut, liver, and skin. The incidence of severe acute GvHD occurs
in 50% of patients who receive a human leukocyte antigen-
matched but unrelated donor allograft, and fewer than 20%
of patients who develop severe GvHD survive 5 years after
transplantation (Kernan et al., 1993). Consequently, the devel-opment of effective treatment of GvHD remains an important
goal in BMT.
Mouse models of GvHD after allogeneic BMT have shown
that both CD4+ T cells (T helper [Th] cells) and CD8+ T cells
(T cytotoxic [Tc] cells) mediate acute GvHD (Vallera et al.,
1994). The traditional model of Th cell differentiation into either
Th1 or Th2 cells has now been modified by the identification of
two additional lineages generated in the presence of transform-
ing growth factor beta (TGF-b) (Weaver and Hatton, 2009). The
first, STAT5-dependent regulatory T (Treg) cells, express the
transcription factor FoxP3 and inhibit inflammatory responses
(Sakaguchi, 2011). Treg cells can be found naturally (natural
Treg [nTreg] cells) in healthy mice, where themajority are derived
during thymic development. Alternatively, FoxP3+ cells can be
induced (induced Treg [iTreg] cells) from naive Th cells by stim-
ulating them in vitro in the presence of TGF-b and interleukin-2
(IL-2) (Chen et al., 2003). The second lineage consists of
STAT3-dependent Th17 cells, which are characterized by secre-
tion of IL-17 and are associated with autoimmune disease
(Bettelli et al., 2007). The roles of these helper cell lineages in
contributing to the pathology of GvHD remain controversial
(Yi et al., 2009). Nonetheless, specific Th cell lineages may
contribute to the organ specificity of GvHD, with Th1 cells medi-
ating gut and liver GvHD (Nikolic et al., 2000), Th2 cells mediating
lung GvHD (Nikolic et al., 2000), and Th17 cells responsible for
skin GvHD (Carlson et al., 2009).
In contrast, Treg cells suppress a wide variety of T cell inflam-
matory diseases, including experimental GvHD mediated by
mouse (Cohen et al., 2002; Edinger et al., 2003) and human
T cells (Amarnath et al., 2010; Mutis et al., 2006). Adoptive
transfer of Treg cells has been proposed as a therapy to prevent
GvHD (June and Blazar, 2006). However, the success of an
adoptive Treg cell therapy response is reliant upon the fidelity
of the transplanted cells, which has recently been called into
question (Tang et al., 2012). This notion of nTreg cell instability
remains a contentious issue, with different groups reaching
opposite conclusions (Rubtsov et al., 2010; Zhou et al., 2009).
Whereas STAT5 is a key positive regulator of FoxP3 expres-
sion, STAT3 is an important inhibitor (Yao et al., 2007). STAT3
binds to a silencer element within the Foxp3 locus and is
associated with a reduction in Smad3 binding (Xu et al., 2010).Immunity 37, 209–222, August 24, 2012 ª2012 Elsevier Inc. 209
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Figure 1. Transplantation with STAT3-
Deficient T Cells Is Associated with an
Enhanced Survival Rate and Reduction in
Acute GvHD.
Three independent experiments, each with at
least four recipients per cohort, were performed
whereby irradiated BALB/c mice were trans-
planted with T-depleted BM cells alone (BM only)
or with 2.53 106 unfractionated T cells from either
Foxp3-GFP;Stat3fl/fl (Control) or Foxp3-GFP;CD4-
Cre;Stat3fl/fl mice (Stat3KO).
(A) Survival post transplantation. A representative
experiment is shown (n = 7 mice per cohort).
(B) Weight loss, expressed as a percentage of the
pretransplant weight. This figure depicts a second
representative experiment (n = 4 per cohort).
Statistics were determined using a two-way
ANOVA test; error bars denote the SEM.
(C) In a third experiment, cohorts were evaluated
for evidence of GvHD by histology at day 14 post-
BMT. Histology criteria for scoring GvHD are listed
in Figure S1 (0, no disease; 4, severe disease).
Histogram columns represent the mean values for
each experiment, and error bars indicate the SD.
Immunity
STAT3 Inhibits FoxP3 Expression in GvHDThe importance of cytokines that signal through STAT3 has
been demonstrated in murine models of GvHD. Lu et al. (2008)
found that allo-activated T cells induced in mouse models of
acute GvHD are characterized by phosphorylation of STAT3.
IL-6, IL-21, and IL-23, cytokines that activate STAT3, are all
necessary for the development of acute GvHD (Bucher et al.,
2009; Chen et al., 2009; Das et al., 2009). Conversely, inhibition
of IL-6 was associated with the appearance of iTreg cells;
however, the potential effects of IL-6 on transferred nTreg cells
were not investigated (Chen et al., 2009).
Given the potential therapeutic importance of Treg cell-based
therapies, we set out to investigate the role of STAT3 in donor
T cells during acute GvHD. We used T cells from Foxp3-GFP
reporter mice, which allowed us track the in vivo fate of the nTreg
and iTreg cell populations in the inflammatory milieu of acute
GvHD.We show that nTreg cells lose expression of FoxP3 within
this inflammatory environment and that this loss of FoxP3 is in
part STAT3-dependent. Finally, the absence of STAT3 permitted
the conversion of transferred naive CD4+ T cells to iTreg cells,
which correlated with a strikingly improved survival rate during
GvHD.
RESULTS
STAT3 in T Cells Is Required for the Development
of Acute GvHD
To explore the role of STAT3 in allogeneic BMT, mice with
a conditional deletion of Stat3 in T cells on a B6 background
were used as a source of donor T cells. We analyzed the effect
of transplanting allogeneic (BALB/c) animals with T-depleted
BM with or without T cells from STAT3-deficient or control
animals. The majority of animals that received T-depleted BM
supplemented with control T cells rapidly lost weight and died210 Immunity 37, 209–222, August 24, 2012 ª2012 Elsevier Inc.within 14 days post-BMT (Figures 1A and 1B). In contrast, all
recipients of T-depleted BM alone or T-depleted BM supple-
mented with STAT3-deficient T cells survived (Figures 1A and
1B) (p < 0.001). Relative to control T cell recipients, STAT3-
deficient T cell recipients had reduced overall GvHD by histo-
logic analysis. STAT3-deficient T cell recipients were particularly
protected against GvHD of the skin and colon (Figure 1C). Thus,
T cell STAT3 signaling was necessary for the development of
acute GvHD. We next sought to determine potential mecha-
nisms underlying the differences in survival.
Colitis of Acute GvHD Is Associated with Reduced
Numbers of Th17 Cells within the Lamina Propria
STAT3 is a critical factor for the generation of Th17 cells (Hira-
hara et al., 2010). A role of IL-17 has been explored in mouse
models of acute GvHD, but its importance remains controversial
(Kappel et al., 2009; Yi et al., 2008).We therefore investigated the
expression of this cytokine in our model of acute GvHD. We
observed a higher proportion of interferon-g (IFN-g)-producing
splenic CD4+ T cells in the setting of allogeneic BMT compared
with syngeneic BMT (Figures 2A and 2B); the increase in IFN-g
secretion was less marked in STAT3-deficient T cells compared
with T cells from control animals (p = 0.006). However, therewere
few IL-17-secreting splenic CD4+ T cells in either syngeneic or
allogeneic BMT; of note, the rare events that were detected
consisted of IL-17+IFN-g+ T cells (Figure 2A, lower left panel).
CD4+ cells from the gut lamina propria (LP) contain abundant
numbers of IL-17+ cells in healthy mice (Ivanov et al., 2006). The
colon was a site where there was a significant difference in the
degree of acute GvHD pathology between mice that received
STAT3-deficient T cells comparedwith control T cells (Figure 1C).
We therefore investigated the influence of STAT3 in colonic LP
T cells harvested during the second week post-BMT. Twelve
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Figure 2. Acute GvHD Is Not Associated with the Presence of Th17 Cells
Irradiated syngeneic (B6) or allogeneic (BALB/c) mice were transplanted with CD45.1+ B6 T-depleted BM cells together with 2.5 3 106 CD4+CD45.2+
unfractionated T cells from either Foxp3-GFP;Stat3fl/fl (Control) or Foxp3-GFP;CD4-Cre;Stat3fl/fl (Stat3KO) mice. IL-17 and IFN-g expression were determined by
intracellular staining in the CD4+CD45.2+ T cell population in spleens and peripheral lymph nodes at day 12 post-BMT. The flow cytometry plots show a repre-
sentative sample (A); the histogram depicts mean values pooled from four mice (B). Data are representative of two separate experiments. The experiment was
repeated two additional times, and IL-17 and IFN-g expression were determined by intracellular staining in the CD4+CD45.2+ T cell population isolated from the
colonic LP. Theflowcytometry plots showa representative sample (C), thehistogramdepictsmeanvaluespooled from fourmice, anderrorbars indicate theSD (D).
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Immunity
STAT3 Inhibits FoxP3 Expression in GvHDdays after syngeneic BMT using control T cells, we observed
that approximately 10% of LP CD4+ lymphocytes secreted
IL-17 (Figure 2C, top left panel); as predicted, recipients of
STAT3-deficient syngeneic T cells had an approximate 90%
reduction in LP CD4+ T cells capable of IL-17 secretion (p =
0.0002) (Figure 2C, top right panel). Surprisingly, in allogeneic
host animals receiving control T cells, there was a profound
reduction in the number IL-17+ LP lymphocytes compared with
that seen in mice receiving syngeneic control T cells (p =
0.00012) (Figure 2D). In summary, recipients of control or
STAT3-deficient allogeneic T cells each had minimal numbers
of IL-17-secreting, LP CD4+ T cells (Figure 2C, lower panels).
The few IL-17+ allogeneic T cells seen in the LP were IL-
17+IFN-g+ T cells. Thus, the inflammatory colitis associated
with acute GvHD, far from being dependent on Th17 cells, was
associated with their reduction. These data further indicate
that the ability of STAT3 to modulate acute GvHD cannot be
explained simply by effects on Th17 cells, thereby implying an
alternative mechanism.
Loss of FoxP3 inRegulatory TCells after Allogeneic BMT
is STAT3-Dependent
We next turned to the fate of Treg cells after BMT, as determined
by FoxP3 expression within the transplanted T cells. An alterna-
tive possibility is that STAT3 was responsible for inhibiting
FoxP3 expression (Xu et al., 2010). We hypothesized that
STAT3-deficient Treg cells would be maintained in vivo, thereby
reducing acute GvHD. Initially, studies were performed to rule
out the possibility that STAT3-deficient mice might contain
nTreg cells that were quantitatively or qualitatively different
from control nTreg cells. To facilitate these studies, FoxP3
expression was determined by GFP fluorescence, as both
STAT3-deficient and control animals contained a Foxp3-GFP
reporter transgene. First, we found that the basal frequency of
FoxP3+ cells was similar in both control and STAT3-deficient
mice (Figures S1A and S1B available online). Second, CpG
methylation in the Treg cell-specific demethylation region
(Floess et al., 2007) was similar in sorted control and STAT3-
deficient nTreg cells (Figure S1C). Third, we found that control
and STAT3-deficient FoxP3+ T cells had a similar capacity to
prevent naive T cell proliferation after T cell receptor stimulation
(Figures S1D and S1E). In addition, control and STAT3-deficient
FoxP3+ T cells had an equivalent capacity to inhibit naive T cell
proliferation (Figure S1F), IFN-g secretion (Figure S1G), and
IL-2 secretion (Figure S1H) in response to fully major-histocom-
patibility-complex-disparate antigen-presenting cells.
As STAT3-deficient nTreg cells were quantitatively and quali-
tatively similar to control nTreg cells in vitro, there existed
sufficient validity to compare whether such T cell populations
were differentially maintained in vivo post-BMT. Administration
of control T cells into syngeneic hosts resulted in a frequency
of FoxP3+ T cells in peripheral lymph nodes at day 14 post-
BMT, which was modestly reduced in recipients of STAT3-
deficient T cells (Figure 3A, left panels). In contrast, administra-
tion of control T cells into allogeneic hosts resulted in a low
frequency of FoxP3+ T cells that was greatly diminished relative
to recipients of STAT3-deficient T cells (p = 0.0002) (Figure 3A,
right panels). Similar results were obtained in an analysis of
colonic LP lymphocytes (Figure 3B); that is, a significant popula-212 Immunity 37, 209–222, August 24, 2012 ª2012 Elsevier Inc.tion of control lymphocytes expressed FoxP3 after syngeneic
BMT, but not allogeneic BMT (p = 0.011), whereas STAT3-
deficient T cells yielded substantial populations of FoxP3+ cells
after both syngeneic and allogeneic BMT.
Instability of Natural T Regulatory Cells during GvHD
We reasoned that the differential numbers of FoxP3+ cells
observed after allogeneic transplant using control versus
STAT3-deficient T cells may have been due to two possibilities:
(1) transferred control Treg cells lost FoxP3 expression or (2)
transferred naive T cells could not be induced into a Treg cell
phenotype after allogeneic BMT. In both cases, this would be
due to STAT3 signaling. With respect to the first possibility,
investigators have reached opposite conclusions in their
respective models of immune-mediated, inflammatory disease
(Oldenhove et al., 2009; Rubtsov et al., 2010; Zhou et al.,
2009). We approached this issue with a variety of BMT condi-
tions (syngeneic versus allogeneic; T cell-depleted versus
T cell-replete).
In the setting of T cell-depleted allogeneic BMT, mice received
a pure (99% FoxP3-GFP+) population of control or STAT3-
deficient nTreg cells, and the fate of the transferred FoxP3+ cells
could be tracked using congenic markers and FoxP3-GFP
expression. Two weeks after the nTreg cells were transferred,
the mice remained healthy, and over 90% of the post-BMT
T cells remained FoxP3+, irrespective of whether the transferred
nTreg cells expressed STAT3 (Figure 4A). In a second experi-
ment, irradiated syngeneic and allogeneic hosts received BM,
nTreg cell-depleted T, and FoxP3+ cells from control animals.
In syngeneic host animals, the cells retained their FoxP3 ex-
pression (Figure 4B, left panel). In contrast, in the presence of
effector T cells within allogeneic hosts, the transferred FoxP3+
cells lost FoxP3 expression (p = 0.021) (Figure 4B, right panel)
and acquired either IL-17 or IFN-g expression. In a third experi-
ment, we explored whether STAT3-deficient Treg cells were
resistant to this conversion in allogeneic host animals. Irradiated
allogeneic hosts were transplanted with BM, nTreg cell-depleted
T, and FoxP3+ cells from control or STAT3-deficient donors.
Consistent with the prior experiments, most of the control nTreg
cells lost FoxP3 expression (Figure 4C, left panel), whereas most
of the STAT3-deficient nTreg cells retained FoxP3 expression
(p = 0.0002) (Figure 4C, right panel).
We next sought to determine whether we could recapitulate
the in vivo loss of FoxP3 in nTreg cells using an in vitro model
that contained inflammatory cytokines elaborated during acute
GvHD. In preliminary experiments, various combinations of
proinflammatory cytokines were tested (data not shown). As
demonstrated in Figure 5A, FoxP3 expression was inhibited
by IL-6 compared with cells cultured in cytokine-free media. Of
note, IL-27 also had the capacity to downregulate FoxP3. IL-6
predominantly exerts its effect via STAT3, and we found that
the ability of IL-6 to downregulate FoxP3 was blocked in the
absence of STAT3. In contrast with IL-6, IL-27 signals principally
through STAT1 (Stumhofer et al., 2006). Accordingly, we found
that the inhibitory effect of IL-27 on FoxP3 expression was in
part independent of STAT3. We next measured cytokine ex-
pression in the converted nTreg cells (Figure 5B). We found
that nTreg cells, which lost FoxP3 expression in the presence
of IL-6, produced IL-17. These data are consistent with previous
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Figure 3. STAT3 Promotes the Loss of Treg Cells during Acute GvHD
Irradiated syngeneic (B6) or allogeneic (BALB/c) mice were transplanted with CD45.1+ B6 T-depleted BM cells together with 2.5 3 106 CD45.2+ unfractionated
T cells from either Foxp3-GFP;Stat3fl/fl (indicated as littermate controls: Control) or Foxp3-GFP;CD4-Cre;Stat3fl/fl mice (indicated as STAT3 knockout: Stat3KO).
FoxP3 expression was determined in the CD45.2+CD45.1CD4+ population from spleen and peripheral lymph nodes at day 14 post-BMT. The flow cytometry
plots show a representative sample, and the histograms denotemean values from four mice derived from two separate experiments (A). In separate experiments,
FoxP3 expression was determined in the CD45.2+CD45.1CD4+ population from the colonic LP. The flow cytometry plots show a representative sample pooled
from three colons; the histogram columns denote mean values and error bars indicate the SD derived from four separate experiments (B). Significance was
determined by paired t testing.
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STAT3 Inhibits FoxP3 Expression in GvHDreports (Huber et al., 2008; Xu et al., 2007). The anti-inflammatory
cytokine IL-10 is an activator of STAT3. However, addition of
IL-10 alone or in conjunction with IL-6 did not alter the pro-
portion of FoxP3+ cells recovered after 6 days in either control
or STAT3-deficient cells (data not shown). This is consistent
with previous reports that demonstrate divergent functions of
IL-6 and IL-10 despite the ability of both cytokines to activate
STAT3 (Murray, 2006).
Several groups have previously shown that STAT5 is essential
for expression of FoxP3. Its actions appear to be direct insofar
as STAT5 binds multiple sites within the Foxp3 locus (Yao
et al., 2007; Zorn et al., 2006). The third STAT5 binding site
(target III) has also been identified as a STAT3 binding site in
both mice and humans (Xu et al., 2010; Zorn et al., 2006). We
considered whether activation of STAT3 would inhibit STAT5
binding to the Foxp3 gene. The data in Figure 5C demonstrate
that significantly more STAT5 bound to this region of Foxp3
locus when STAT3 was not present (p = 0.002).STAT3-Deficient nTreg Cells Fail to Rescue Acute GvHD
Despite their Persistence
The differential expression of IL-17 seen in nTreg cells that lost
FoxP3 expression in the presence of IL-6 versus IL-27 led us
to characterize the cytokine-secretion profile of the transferred
nTreg cell population. Irradiated allogeneic BALB/c mice
received BM transplants containing a mixture of effector and
natural T cells that could be differentiated by congenic markers.
Ten days post transplant, IFN-g and IL-17 expression were
determined in the CD45.1+ (effector T) and CD45.2+ (nTreg)
cell populations. As shown in Figure 2, a substantial population
of effector T cells expressed IFN-g, and a few cells stained posi-
tive for IL-17 (Figure 6A, left panels). In contrast, the control
nTreg cells that had lost FoxP3 expression had a different
pattern of cytokine expression: relative to effector cells, these
converted nTreg cells became IL-17 producers more frequently
(p = 0.024) and had a reduced propensity to express IFN-g (p =
0.04) (Figure 6A, right panels; Figure 6B). It is important to noteImmunity 37, 209–222, August 24, 2012 ª2012 Elsevier Inc. 213
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Figure 4. STAT3 Promotes the Loss of
FoxP3 Expression in nTreg Cells during
Acute GvHD
Irradiated allogeneic (BALB/c) mice were trans-
planted with CD45.1+ B6 T-depleted BM cells
together with 0.53 106CD45.2+CD4+FoxP3-GFP+
T cells from either Foxp3-GFP;Stat3fl/fl (Control)
or Foxp3-GFP;CD4-Cre;Stat3fl/fl mice (Stat3KO).
FoxP3 expression was determined in the CD4+
CD45.2+CD45.1H2kb+ population at day 14 post
BMT. Flow cytometry plots show a representative
sample; the histogram depicts mean values and
error bars denote the SD from three mice pooled
from two separate experiments (A). Irradiated
syngeneic (B6) or allogeneic (BALB/c) mice were
injected with CD45.1+ B6 T-depleted BM cells
together with 23 106 CD45.1+CD25wild-type B6
T cells and 0.5 3 106 CD45.2+CD4+FoxP3-GFP+
T cells from Foxp3-GFP;Stat3fl/fl mice. FoxP3
expression was determined in the CD4+CD45.2+
CD45.1 population at day 10 post BMT. Flow
cytometry plots show a representative sample;
the histogram represents mean values and error
bars denote the SD from three mice each derived
from an independent experiment (B). Significance
was determined by a two-tailed paired t test.
Irradiated allogeneic (BALB/c) mice were injected
with CD45.1+ B6 T-depleted BM cells together
with 2 3 106 CD45.1+CD25 wild-type B6 T cells
and 0.5 3 106 CD45.2+CD4+FoxP3-GFP+ T cells
from either Foxp3-GFP;Stat3fl/fl (Control) or Foxp3-
GFP;CD4-Cre;Stat3fl/fl (Stat3KO) mice. FoxP3
expression was determined in the CD4+CD45.2+
CD45.1H2Kb+ population at day 10 post-BMT.
The flow cytometry plots show a representative
sample, the histogram indicates mean values, and
error bars denote the SD pooled from three mice
derived from two separate experiments (C).
Immunity
STAT3 Inhibits FoxP3 Expression in GvHDthat the proportion of cells derived from the transferred CD45.2+
nTreg cell population made up less than 4% of the total CD4+
population, irrespective of whether the transferred cells were
from control or STAT3-deficient animals (Figure S2). The total
numbers of transferred FoxP3+ nTreg, FoxP3IFN-g+, and
FoxP3IL-17+ cells are indicated in Figure 6C. Although consis-
tent with the data in Figures 4C and 5B, only the differences in
IL-17 expression were significant (p = 0.046).
Recently, work by Miyao and colleagues has demonstrated
that not all FoxP3GFP+ nTreg cells express high amounts of
CD25 and that CD25FoxP3+ cells are less able to retain
FoxP3 expression compared with CD25hiFoxP3+ cells (Miyao
et al., 2012). In view of this, we investigated the proportion of
FoxP3+ nTreg cells that expressed CD25 in control and
STAT3-deficient T cells and found no difference in CD25
expression (Figure S3). Next, we repeated the experiments
described in Figure 6 using CD25hiFoxP3+ nTreg cells, which
were transplanted into irradiated allogeneic host animals
together with congenic naive CD4+ T cells. Consistent
with our earlier work, a substantial proportion of control
CD25hiFoxP3+ nTreg cells lost FoxP3 expression after 10 days
(Figure S3).214 Immunity 37, 209–222, August 24, 2012 ª2012 Elsevier Inc.Next, we evaluated whether STAT3-deficient nTreg cells
would be better able to control GvHD induced by coadminis-
tered T cells. We transplanted mice with nTreg cells and effector
T cells, as previously described (Edinger et al., 2003); in this
setting, we then compared the ability of wild-type and STAT3-
deficient nTreg cells to inhibit GvHD. The data in Figure 6D
demonstrate that coadministration of STAT3-deficient nTreg
cells, despite the maintenance of FoxP3+ expression in the
natural Treg cell pool post-BMT, did not improve survival
compared with recipients of wild-type nTreg cells. From this,
we concluded that neither the retention of FoxP3 expression
nor the expression of inflammatory cytokines by the converted
control nTreg cells was sufficient to explain the survival benefit
seen in allogeneic mice transplanted with STAT3-deficient
T cells.
STAT3 Blocks the Generation of iTreg Cells
in the Inflammatory Environment of GvHD
We investigated the second possibility, namely, that STAT3-
deficient naive Th cells might be predisposed to become iTreg
cells. The ability of naive cells to acquire FoxP3 has been noted
in a number of circumstances both in vitro (Chen et al., 2003)
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Figure 5. STAT3 Promotes the Loss of FoxP3 Expression in nTreg Cells In Vitro
CD4+FoxP3-GFP+ cells were isolated from Control and Stat3KO mice (left panels) and stimulated with anti-CD3 and anti-CD28 for 6 days in the presence of
media alone or with IL-6 or IL-27. FoxP3 expression was determined by GFP expression. Data are representative of two experiments (A). The control cells
were subsequently stained for FoxP3 and IL-17 expression; the data are representative of two separate experiments (B). Sorted CD4+FoxP3+ iTreg cells
were stimulated with IL-2 and IL-6, crosslinked, and immunoprecipitated with anti-STAT5. Target site III within the Foxp3 locus was amplified along with
a control site (site IV). Histograms denote mean values and error bars indicate SD from a single experiment, and the data are representative of two separate
experiments (C). Cartoon representation of the Foxp3 locus illustrating target sites III and IV by Yao et al. (2007) and the enhancer sites identified by Xu et al.
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the fate of purified, naive, FoxP3 Th cells isolated from control
and STAT3-deficient donors was tracked after syngeneic and
allogeneic transplantation. After syngeneic BMT, recipients of
control and STAT3-deficient naive FoxP3 T cells had similar
reconstitution with FoxP3+ T cells (Figure 7A, left panels). In
marked contrast, after allogeneic BMT, FoxP3 induction was
greatly diminished in recipients of control T cells, but relatively
preserved in recipients of STAT3-deficient T cells (p = 0.007)
(Figure 7A, right panels). Thus, the inflammatory environment
within allogeneic host animals appeared to inhibit the induction
of FoxP3 expression in transferred naive T cells, and STAT3
was necessary for this inhibition.
We next explored whether a mixture of wild-type and STAT3-
deficient T cells would alter the ability of STAT3-deficient naive
T cells to acquire FoxP3 in allogeneic hosts. To test this, equal
proportions of naive wild-type CD45.1+ Th cells and CD45.2+
Th cells from control or STAT3-deficient animals were trans-
ferred into irradiated allogeneic hosts. Consistent with previous
experiments, we found that there was no significant difference
in the total number of recovered CD4+ T cells between all
three groups; however, the ratio of CD45.1+/CD45.2+ cells was
higher if the CD45.2+ population was STAT3-deficient (p =
0.022) (Figure 7B). Next, we determined the percentage of naive
T cells that had acquired FoxP3 in the CD45.2+ population.
We found that the likelihood of acquiring FoxP3 expression
was significantly higher (p = 0.025) if the cells lacked STAT3
compared with control cells, irrespective of the presence of
wild-type T cells (Figure 7C). Similarly, the presence of STAT3-
deficient cells did not alter the inability of wild-type T cells to
acquire FoxP3 (Figure S4A).
Finally, we evaluated whether the STAT3-dependent inhi-
bition of iTreg cell differentiation posttransplant was associated
with the development of lethal GvHD. Irradiated mice received
allogeneic BM together with naive CD4+ T cells. Allogeneic
hosts that received wild-type naive CD4+ T cells rapidly lost
weight and died in the first 2 weeks post-BMT (Figure 7D). In
contrast, recipients of STAT3-deficient naive CD4+ T cells
were protected against GvHD lethality (p = 0.037). After
10 days post-BMT, the total numbers of CD4+ T cells were
determined: there were no significant differences, regardless
of whether the mice had received control or STAT3-deficient
T cells (Figure S4B). Therefore, in the absence of transferred
nTreg cells, the development of iTreg cells within the mice
receiving STAT3-deficient T cells appeared to be sufficient to
limit lethal GvHD.
DISCUSSION
Acute GvHD remains a principal cause of post-BMT morbidity
and mortality. Supplementation of transplanted BM with nTreg
cells has been proposed as a strategy to reduce acute GvHD,
in addition to other immune-mediated diseases (June and
Blazar, 2006). Nonetheless, the potential success of these novel
approaches is predicated on phenotypic stability of Treg cells
and their resistance to the action of inflammatory cytokines
elaborated during GvHD. In this study, we have demonstrated
that murine recipients of an allogeneic BMT with T cells deficient
in STAT3 had a significantly prolonged survival compared withanimals that received an allogeneic transplant with control
T cells.
The discovery of Th17 cells has provided insights into mecha-
nisms of immune-mediated disease, and the importance of
STAT3 in the generation of Th17 cells has been substantiated
in both mouse and humans (Hirahara et al., 2010). We therefore
first considered that the beneficial anti-GvHD effect of trans-
planting STAT3-deficient T cells was probably related to their
inability to produce IL-17. However, several findings argue
against this as the major mechanism operational in our model.
First, we found that cytokine expression after allogeneic BMT
was similar in recipients of control or STAT3-deficient T cells.
Second, we found a striking difference in the number of Th17
cells within the colonic LP of syngeneic animals and allogeneic
animals transplanted with wild-type T cells; of note, this com-
parison was not explored in previous work (Bucher et al., 2009;
Chen et al., 2009; Das et al., 2009). Compared with syngeneic
hosts, there were remarkably few IL-17-secreting CD4+ T cells
in allogeneic hosts despite severe acute GvHD. This indicated
that IL-17 was not a major mediator of acute GvHD in our model,
and is consistent with the finding that deleting Il17 in T cells
has only minor effects in acute GvHD (Kappel et al., 2009). In
summary, these findings suggest that the inflammatory colitis
associated with acute GvHD is not dependent on Th17 cells
and further suggest that the beneficial effect of deleting STAT3
in donor T cells cannot be attributed to inhibition of Th17 cells.
Previous studies have indicated that administration of nTreg
cells can reduce the severity of murine acute GvHD and other
autoimmune diseases (Cohen et al., 2002; Edinger et al., 2003).
Given this literature, it is interesting to note that one of our
most dramatic findings was the loss of FoxP3+ in transplanted
nTreg cells, with their subsequent conversion into cytokine-
producing effector cells. The phenomenon of Th cell lineage
plasticity has been the subject of much interest and research
activity (Wei et al., 2009). A number of groups have explored
the stability of FoxP3 expression in nTreg cells, and recent
publications have made the subject more rather than less con-
troversial. Several groups have shown that in the presence of
inflammation, FoxP3 expression is either inhibited or lost (Olden-
hove et al., 2009; Zhou et al., 2009). Zhou et al. (2009), using
Foxp3-GFP reporter animals expressing a diabetogenic T cell
receptor, demonstrated that one-third of adoptively transferred
Treg cells lost FoxP3 expression and became effector cells.
In contrast, FoxP3 has been reported as able to induce its
own expression, and nTreg cells have been shown to remain
FoxP3+ following adoptive transfer into healthy host animals
(Gavin et al., 2007). Using a similar reporter strategy, Rubtsov
et al. (2010) noted that nTreg cells remained FoxP3+ in a number
of inflammatory environments, including Listeriamonocytogenes
infection, the NOD.BDC2.5 model of type 1 diabetes, and the
K/BxN model of inflammatory arthritis.
Recently, work by Miyao and colleagues has argued that
a small proportion of FoxP3+ Th cells that are CD25 may be
responsible for this controversy (Miyao et al., 2012). However,
we believe the present work supports the contention that nTreg
cells may truly be destabilized. We believe that our findings
represent actual, rapid conversion of FoxP3+ cells into FoxP3
cells; that is, using flow cytometry sorting, we transferred pure
populations of nTreg cells and were able to reliably differentiateImmunity 37, 209–222, August 24, 2012 ª2012 Elsevier Inc. 217
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Figure 7. The Generation of FoxP3+ iTreg Cells in the Absence of STAT3 Correlates with Survival in GvHD
Irradiated syngeneic (B6) or allogeneic (BALB/c) mice were transplanted with CD45.1+ B6 T depleted BM cells together with 2.5 3 106 CD45.2+CD4+ naive
(CD62L+CD44FoxP3) T cells from either Foxp3-GFP;Stat3fl/fl (Control) or Foxp3-GFP;CD4-Cre;Stat3fl/fl mice (Stat3KO). FoxP3 expression was determined in
the CD45.2+CD45.1CD4+ population. Mice were assessed 12 days post transplant. Flow cytometry plots show a representative sample; the histogram shows
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markers. In the absence of effector cells and the associated
GvHD, more than 90% of the transferred nTreg cells maintained
FoxP3 expression. When effector T cells were added, FoxP3
expression was maintained in syngeneic hosts but was essen-
tially extinguished in allogeneic host animals. Furthermore, we
obtained similar results using CD25hi nTreg cells; thus, we
do not believe the results are explained by the outgrowth of
Foxp3+CD25 cells. We conclude that the ability of STAT3
to sense an inflammatory environment is a key factor in the
phenotypic destabilization of nTreg cells. This biology may
have important clinical translational significance: in the setting
of profound immune cell activation, the approach of merely
providing Treg cells may prove problematic as long as STAT3-
activating cytokines are present.
There remains the question of precisely how STAT3 serves
to inhibit FoxP3 expression in T cells. The present work substan-
tiates previous findings that nTreg cells may be destabilized
in vitro in a STAT3-dependent manner (Xu et al., 2007; Xu
et al., 2010; Yang et al., 2008). Zorn and colleagues first iden-
tified a region in the Foxp3 locus that binds both STAT3 and
STAT5 (Zorn et al., 2006) at a site that we thereafter referred to
as target site III (Yao et al., 2007). Subsequently, Xu et al.
(2010) argued that this site resides within a second enhancer
region and mediates the inhibitory actions of STAT3 on FoxP3
gene transcription. In the present work, we show that presence
of STAT3 inhibits STAT5 binding to this element. In contrast
with the action of STAT3, STAT5 is known to both promote
and maintain iTreg cell FoxP3 expression (Chen et al., 2011). In
the setting of T. gondii infection, Oldenhove and colleagues
have demonstrated that Treg cell numbers decline, an effect
that was reversed by the addition of IL-2, a potent inducer of
STAT5 (Oldenhove et al., 2009). Forced expression of STAT5 in
donor T cells has been shown to protect mice from acute
GvHD by enhancing the induction of Treg cells (Vogtenhuber
et al., 2010). Taken together, our data support the notion that
the inhibitory actions of STAT3 may act in part by interfering
with the ability of STAT5 to bind to the Foxp3 locus and promote
gene expression, thereby providing an important mechanism
by which STAT3 can destabilize Treg cells.
We were struck by the finding that STAT3-deficient nTreg
cells, in spite of their in vivo persistence, were no more effective
than wild-type nTreg cells in ameliorating GvHD. Chaudhry et al.
(2009) found that STAT3-deficient nTreg cells were functionally
impaired in vivo, although their primary defect related to
impaired ability to constrain IL-17-mediated pathology. Consis-
tent with this prior publication, we noted that STAT3-deficient
nTreg cells suppressed T cell proliferation in vitro to an extentmean values and error bars denote SD pooled from four mice derived from two se
with CD45.1+ B6 T-depleted BM cells together with 1 3 106 CD45.1+CD4+ naive
(CD62L+CD44FoxP3) T cells from either Foxp3-GFP;Stat3fl/fl (WT/Control), Fo
T-depleted BM cells together with 2 3 106 CD45.1+CD4+ naive (CD62L+CD44
CD45.2+CD4+ T cells were determined in all three groups 10 days post transpla
the WT/Control and WT/Stat3KO groups (right histogram); the histograms depict
expression was determined in the CD4+CD45.2+CD45.1H2Kb+ populations in
histogram represent mean values and error bars denote SD pooled from four m
rescued with T-depleted BM cells and 2.53 106 CD4+ naive (CD62L+CD44FoxP
Cre;Stat3fl/fl mice (Stat3KO; n = 5). Transplanted mice were assessed for survivalsimilar to that of control nTreg cells. Subsequently, it has been
shown that STAT3-deficient nTreg cells have reduced in vivo
efficacy due to a deficiency in IL-10 secretion (Chaudhry et al.,
2011; Huber et al., 2011). As previous studies found that Treg
cells inhibit GvHD in part through their secretion of IL-10
(Hoffmann et al., 2002), it is possible that a deficiency in IL-10
secretion in STAT3-deficient nTreg cells may account in part
for their inability to inhibit GvHD in spite of preservation of
FoxP3 expression.
Despite the finding that transferred STAT3-deficient nTreg
cells did not improve the prognosis during acute GvHD,
administration of STAT3-deficient naive T cells was sufficient
to significantly improve survival rates, even in the absence of
any transferred nTreg cells. In our model of GvHD, wild-type
donor cells principally became effector T cells. However,
a substantial portion of transplanted STAT3-deficient T cells
induced FoxP3 expression, thus acquiring an iTreg cell pheno-
type. This observation is consistent with our previous report
using a T cell transfer model of colitis (Durant et al., 2010). Taken
together, these results argue that STAT3-signaling cytokines
limit the numbers of FoxP3+ T cells by two pathways: (1)
enhanced instability of nTreg cells and (2) failure to generate
new iTreg cells from naive CD4+ T cells. In the context of a
profound immune disease such as GvHD, the appearance of
iTreg cells from naive precursors appears to be of paramount
importance for improving the prognosis, whereas the simple
provision of even a STAT3-deficient nTreg cell may have limited
therapeutic efficacy.
The present data further explain the beneficial effects of
blocking IL-6 during GvHD (Chen et al., 2009). Transplantation
with STAT3-deficient naive T cells resulted in an accumulation
of iTreg cells, similar to that seen during IL-6 blockade. In our
study, it was the promotion of iTreg cell accumulation, rather
than protection of the nTreg cell phenotype, that represented
the primary pathway whereby STAT3-deficient T cells limited
the pathology associated with acute GvHD. These data provide
further mechanistic rationale for efforts to prevent GvHD by
direct inhibition of STAT3 expression or DNA binding, or indirect
inhibition of STAT3 via combination neutralization of IL-6, IL-21,
and IL-23.
EXPERIMENTAL PROCEDURES
Mice
CD45.1+ C57BL/6 (B6) and BALB/c mice were purchased from the Jackson
Lab (Bar Harbor, ME, USA). Foxp3-GFP B6 reporter mice were obtained
from M. Oukka, Harvard Medical School, Cambridge, MA (Bettelli et al.,
2006), and Stat3fl/fl animals were obtained from D.E. Levy (New York Univer-
sity) (Lee et al., 2002). Stat3fl/fl animals were initially crossed with CD4-Creparate experiments (A). Irradiated allogeneic (BALB/c) mice were transplanted
(CD62L+CD44CD25) wild-type B6 T cells and 1 3 106 CD45.2+CD4+ naive
xp3-GFP;CD4-Cre;Stat3fl/fl mice (WT/Stat3KO), or transplanted CD45.1+ B6
FoxP3) T cells (Stat3KO) alone. The total numbers of CD45.1+CD4+ and
nt (left histogram), and the ratio of CD45.1+ to CD45.2+ T cells is indicated in
mean values and error bars denote SD pooled data from four mice (B). FoxP3
all three groups. Flow cytometry plots show a representative sample; the
ice derived from two separate experiments (C). Irradiated BALB/c mice were
3) T cells from either Foxp3-GFP;Stat3fl/fl (Control; n = 8) or Foxp3-GFP;CD4-
. Data represent survival curves pooled from two independent experiments (D).
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(STAT3KO, STAT3-deficient) and Foxp3-GFP;Stat3fl/fl littermate controls
(control) (Durant et al., 2010). Animals were handled in accordance with the
protocols approved by the National Cancer Institute (NCI) animal care and
use committee.
BMT
BM was flushed from CD45.1 B6 donor femurs and tibias and T cell-depleted
using negative selection by MACS beads (Miltenyi Biotec, Bergisch Gladbach,
Germany). Host allogeneic (BALB/c) or syngeneic (B6) mice were conditioned
with total-body irradiation of 950 cGy in two divided doses 3 hr apart before
being rescued with 5 3 106 BM cells together with 2.5 3 106 T cells from
either STAT3-deficient or control donors. For experiments wherein mice
were transplanted with nTreg cells, CD4+CD45.2+FoxP3-GFP+ cells were
purified by flow cytometry using a FACSaria cell sorter (BD Biosciences,
San Diego, CA, USA). A combination of 5 3 105 Treg cells and 5 3 106
T-depleted BM cells were transplanted alone or in combination with 2 3 106
(Figures 5A–5C) or 1 3 106 (Figure 5D) CD25CD45.1+ T cells isolated by
MACS-bead isolation. Flow cytometry was used to determine the proportion
of FoxP3-GFP+ transplanted T cells that remained FoxP3+ 2 weeks post-
BMT. The transferred B6 FoxP3 cells were differentiated from BALB/c host
cells by expression of H-2Kb; both populations could be differentiated from
transferred B6 BM and effector T cells by use of congenic markers (CD45.1
for transferred T-depleted B6 BM and CD25 T cells; CD45.2 for transferred
nTreg cells and for host identification).
Analysis of Murine Lymphocytes
Mice were analyzed 10–14 days after BMT. Splenocytes and peripheral lymph
node cells were either analyzed directly or after sorting, using Thy1.2+ antibody
and MACS beads. Colonic LP cells were isolated as described previously
(Durant et al., 2010). In brief, large intestines were removed, cleared of
mesentery, fat, and Peyer’s patches, cut into pieces, and washed in Hank’s
balanced salt solution (HBSS) without Ca2+ or Mg2+. After incubation in
HBSS with EDTA, epithelial layer cells were removed, and the remaining
tissue was digested with liberase and DNase I (both Roche, Indianapolis,
IN, USA) at 37C. LP lymphocytes were recovered from the supernatant and
purified over a 40%:80% Percoll gradient.
Cell Sorting and Flow Cytometry
Unless stated otherwise, GFP fluorescence was used to determine FoxP3
expression in peripheral lymphocytes both pre- and posttransplantation.
Intracellular staining on stimulated cells was used to determine cytokine
expression in cells recovered during the second week post transplant.
Cells were first stimulated with phorbol ester and ionomycin (Sigma-Aldrich,
St. Louis) alone for 2 hr; then, for the next 2 hr, GolgiPlug was added
(BD Biosciences). Flow-cytometry-staining antibodies for CD4, CD25,
CD62L, CD45.1, CD45.2, H2Kb, IFN-g, and IL-17 were purchased from BD
Biosciences. Data were acquired using a CyAn flow cytometry machine.
In Vitro Cell Culture
Natural Treg cells, isolated by flow cytometry sorting for CD4+FoxP3-GFP+
expression, were stimulated in cell-culture plates coated with anti-CD3 and
anti-CD28 (10 mg/ml each) for 6 days in cell-culturemedia alone (RPMI, supple-
mented with 10% fetal calf serum, glutamine, 2-mecaptoethanol, penicillin,
and streptomycin) or in the presence of IL-6 (100 ng/ml) or IL-27 (20 ng/ml);
the cytokines were added on days 1 and 4 of cell culture. Induced Treg cells
were cultured fromCD4+ naive (CD62L+CD44FoxP3-GFP) T cells. The naive
T cells were incubated in cell-culture plates coated with anti-CD3 and anti-
CD28 containing cell-culture media with TGF-b (10 ng/ml), IL-2 (100 IU/ml),
anti-IL-4 (10 mg/ml), and anti-IFN-g (10 mg/ml) for 3 days. Cells were subse-
quently sorted for GFP expression. Cytokines were purchased from R&D
Systems (Minneapolis); cytokine antibodies were purchased from Bio X Cell
(West Lebanon, NH, USA).
Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed as described previously
(Yao et al., 2007). Flow-cytometry-sorted CD4+FoxP3-GFP+ iTreg cells
were stimulated with IL-2 (100 IU/ml) and IL-6 (20 ng/ml) for 2 hr, followed220 Immunity 37, 209–222, August 24, 2012 ª2012 Elsevier Inc.by crosslinking for 15 min with 1% formaldehyde. The cells were harvested
and lysed by sonication. After preclearing with protein A agarose beads
(Upstate), cell lysates were immunoprecipitated with anti-H3K4m3 (ab8580,
Abcam) and anti-STAT5A/STAT5B (PA-ST5A and PA-ST5B, R&D Systems)
overnight at 4C. After washing and elution, crosslinks were reversed at
65C for 4 hr. The eluted DNA was purified, samples were analyzed by
quantitative PCR with customer-designed primers, and probes were directed
against target site III (50-ACAACAGGGCCCAGATGTAGA-30, 50-GGAGGTT
GTTTCTGGGACATAGA-30, and 50-6FAM-CCCGATAGGAAAACA-30) and
target site IV (50-CACCAAAGGCTGGAAGCCT-30, 50-CAGACGAGCCTCCA
CAGAGTT-30, and 50-6FAM-CCGTGCCTTGTCAGG-30) as defined previously
using a 7500 real-time PCR system (both Applied Biosystems). The cycle
threshold value for each sample was normalized to the corresponding input
value.
Histological Analysis
Representative samples of skin, liver, intestine, and lung were obtained from
transplant recipients and fixed in 10% formyl saline. Samples were embedded
in paraffin, sectioned, and stained with hematoxylin and eosin. All slides were
coded and read by an external pathologist in a blinded fashion. A four-point
scale of GvHD severity was used to score the samples (specific histology
criteria is detailed in Supplemental Experimental Procedures).
Statistical Analysis
Unless stated otherwise, p values from data presented as histograms were
determined using a two-tailed unpaired t test. p values from survival-curve
data were determined using the log rank test. Unless stated otherwise, histo-
gram columns represent the mean values for each experiment, and error bars
indicate the SD. A single asterisk (*) denotes p < 0.05, a double asterisk (**)
denotes p < 0.01, and a triple asterisk (***) denotes p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.immuni.2012.05.027.
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